Abstract
Objective. To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity. Methods. A panel of four endometrial carcinoma cell lines was treated with variable concentrations of gemcitabine, gemcitabine and cisplatin, or gemcitabine and carboplatin. 3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were performed to determine the IC 50. Results. Each cell line evaluated revealed a dose-dependent decrease in cell growth for gemcitabine alone and in combination with platinum agents. The IC 50 of gemcitabine with cisplatin was significantly lower than that of gemcitabine alone for all cell lines, including the platinum-resistant line. Conclusion. Gemcitabine exerts in vitro cytotoxicity on endometrial cancer cell lines, and the combination of gemcitabine and cisplatin is superior to gemcitabine alone. This may represent a promising option for treatment of endometrial cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
